GNBTinactive

GENEREX BIOTECHNOLOGY CORP

Healthcare·Oncology·Phase 2
OncologyInfectious DiseaseMetabolic

GENEREX BIOTECHNOLOGY CORP (GNBT): 3 pipeline candidates · ~1 mo cash runway. Updated within the last hour.

5.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway0.3

0.9 months

Financial Health7.9

D/E -1.87 · 21% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for GENEREX BIOTECHNOLOGY CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$1.7M

Quarterly Burn

$6.3M

Runway

0.9 mo

Revenue

$21K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2026
Today~7 mo out
Catalyst within runway

Pipeline (3 candidates)

DrugPhase
ae37Phase 2
ii-key-sars-cov-2 coronavirus peptide vaccinePreclinical
oral-lynPreclinical

Frequently asked questions

How many drug candidates are in GENEREX BIOTECHNOLOGY CORP's pipeline?

GENEREX BIOTECHNOLOGY CORP (GNBT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is GENEREX BIOTECHNOLOGY CORP's lead drug candidate?

GENEREX BIOTECHNOLOGY CORP's most advanced tracked candidate is ae37 (Phase 2) for Breast cancer.

What is GENEREX BIOTECHNOLOGY CORP's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, GENEREX BIOTECHNOLOGY CORP has approximately 0.9 months of cash runway.

Get the full picture on GENEREX BIOTECHNOLOGY CORP

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar